XML 23 R7.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 31, 2018
Cash Flows from Operating Activities:      
Net income $ 76,526 $ 55,019 $ 45,572
Non-cash items:      
Depreciation and amortization 110,289 109,418 89,247
Impairment of assets 50,599 21,170 2,673
Share-based compensation expense 20,454 17,188 13,025
Gain on divestiture (8,083) 0 (8,000)
Deferred tax (benefit) provision (6,958) 13,351 (5,828)
Unrealized (gain) loss from hedging activities 813 (24) (649)
Provision for losses on accounts receivable 373 2,111 208
Other non-cash operating activities (1,234) 3,798 4,123
Change in operating assets and liabilities:      
Change in accounts receivable 18,863 (38,064) 5,087
Change in inventories (84,721) (39,322) 14,385
Change in prepaid income taxes 1,480 (3,594) 1,436
Change in other assets and other liabilities (2,876) 494 17,670
Change in accounts payable and accrued expenses (17,308) 17,736 41,401
Net cash provided by operating activities 158,217 159,281 220,350
Cash Flows from Investing Activities:      
Capital expenditures (48,758) (118,961) (74,799)
Proceeds from divestiture 9,808 0 9,000
Proceeds from sale of property, plant and equipment 16,774 2,813 2,758
Acquisition 35,000 0 0
Net cash used in investing activities (57,176) (116,148) (63,041)
Cash Flows from Financing Activities:      
Term loan borrowings 0 347,780 0
Repayment of term loan borrowings (13,125) (266,853) (61,654)
Net increase in short-term loans 45,000 15,000 671
Proceeds from employee stock purchase plan 3,369 3,254 3,246
Proceeds from exercise of stock options 8,647 10,191 37,094
Share repurchases (175,000) (160,000) (100,000)
Other financing activities (99) 0 0
Net cash used in financing activities (131,208) (50,628) (120,643)
Effect of exchange rates on cash and cash equivalents (1,873) (3,323) 3,939
Net Change in Cash and Cash Equivalents (32,040) (10,818) 40,605
Cash and Cash Equivalents at Beginning of Year 169,351 180,169 139,564
Cash and Cash Equivalents at End of Year 137,311 169,351 180,169
Supplemental Disclosures of Cash Flow Information:      
Interest paid 12,545 13,116 7,663
Income taxes paid 11,507 8,205 9,083
Transfers from inventory to fixed assets for placement of Haemonetics equipment 14,479 16,345 8,963
Tenant improvement allowances excluded from capital expenditures $ 5,660 $ 0 $ 0